Healthcare / BiotechnologyWarsaw
$3.20
-0.08 (-2.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.6M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$36M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.7%
↓Gross Margin
83.3%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-43.3%
FCF CAGR
—
FCF margin
-689.5%
FCF / Net income
3.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.6M · net income $-2.8M · FCF $-10.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.6M | $1.6M | $1.3M | $19.0M | $15.2M |
| Net Income | $-2.8M | $-2.8M | $-15.9M | $-1.6M | $-4.6M |
| EBITDA | $-2.6M | $-2.6M | $-11.3M | $-129000.00 | $-3.6M |
| EPS | — | — | -1.60 | -0.14 | -0.41 |
| Gross Margin | 83.3% | 83.3% | 69.4% | 54.3% | 51.5% |
| Operating Margin | -207.4% | -207.4% | -249.0% | -2.6% | -26.5% |
| Net Margin | -175.6% | -175.6% | -1268.3% | -8.3% | -30.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.01 | -0.08 | -0.16 |
| Current Ratio | 9.20 | 9.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.9M | $-10.9M | $29.5M | $1.6M | $-3.5M |
| Returns | |||||
| ROE | -28.7% | -28.7% | -68.5% | 24.2% | 94.4% |
| Valuation | |||||
| P/B | 3.69 | 3.69 | 3.21 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 26.1% | 26.1% | -93.4% | 25.0% | — |
| EPS Growth | — | — | -1042.9% | 65.9% | — |
| Dividend Yield | 71.9% | 71.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+63.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.60 → n/d
Residual
-8.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.